Armour Thyroid vs Cytomel (Liothyronine): Titration Speed and Tolerability Compared

What Are These Two Drugs?

Armour Thyroid is a prescription desiccated thyroid extract (NDT) derived from porcine thyroid glands. Each 60 mg (1 grain) tablet contains 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3) [1]. The T4 component converts peripherally to additional T3 over hours to days, producing a sustained hormonal effect.

Cytomel is the brand name for synthetic liothyronine, a pure T3 preparation. It contains no T4. The FDA-approved labeling lists starting doses of 25 mcg once daily for hypothyroidism, with titration by 12.5 to 25 mcg every 1 to 2 weeks as tolerated [2].

The Core Pharmacological Difference

T4 is a prohormone. Its half-life is approximately 7 days, which buffers serum levels and reduces peak-to-trough swings [3]. T3 is the active hormone at the nuclear receptor. Its half-life is only about 1 day, meaning serum concentrations rise and fall with each dose [4].

Armour delivers both. Cytomel delivers only T3, making its pharmacokinetics sharper and its titration more technically demanding.

How Bioavailability Differs

Oral T4 (from Armour) absorbs at roughly 70 to 80% under fasting conditions [5]. Oral T3 (liothyronine) absorbs at 95% or higher, which partly explains why Cytomel produces a faster and more pronounced serum spike [6]. A 2019 pharmacokinetic analysis in Thyroid confirmed that peak serum T3 after a single liothyronine dose occurs at 2.5 hours post-ingestion and returns toward baseline by 8 hours [7].

Titration Speed: How Fast Can You Adjust Each Drug?

Titration speed differs substantially between these two agents, and the difference has real clinical consequences for both symptom management and safety.

Armour Thyroid Titration Protocol

The American Thyroid Association's 2014 guidelines recommend starting Armour at 30 mg daily and increasing by 15 mg every 4 to 6 weeks, guided by clinical response and TSH [8]. Most patients reach their maintenance dose over 3 to 5 months. The built-in T4 reservoir dampens oscillations: even if a patient misses a dose, circulating T4 sustains T3 production for several days.

The slow pace feels frustrating to some patients. However, it also provides a natural safety buffer. Overshooting is less likely when each dose step takes weeks to fully stabilize.

Cytomel Titration Protocol

The FDA-approved prescribing information for Cytomel supports titration every 1 to 2 weeks [2]. In practice, many endocrinologists use 2 to 4 week intervals because T3 peaks occur so rapidly that patient-reported symptoms (palpitations, heat intolerance, anxiety) can surface within 24 to 48 hours of an increase [9].

Liothyronine is almost always split into two or three daily doses. A common initiation protocol uses 5 mcg twice daily, then increases to 10 mcg twice daily, then 12.5 to 25 mcg twice daily based on free T3 levels and symptom burden [10]. The 2012 European Thyroid Association guidelines on hypothyroidism specify that "the starting dose of liothyronine should not exceed 20 mcg daily in most adults" to reduce cardiovascular risk from acute T3 surges [11].

Head-to-Head Titration Speed Summary

Armour Thyroid reaches steady state approximately 6 weeks after each dose change, owing to T4's long half-life. Cytomel reaches a new steady state in 3 to 5 days after each change, because T3's half-life is roughly 24 hours [4]. That means Cytomel is pharmacokinetically faster, but clinically that speed requires tighter monitoring, not looser.

Tolerability: Side Effects and Who Tolerates What

Tolerability is where these drugs diverge most in real-world use. The key variable is the serum T3 peak that occurs after each oral dose.

Cardiovascular Tolerability

A 2019 study in JAMA Internal Medicine (N=3,435 levothyroxine users who added liothyronine) found that combination T4/T3 therapy was associated with a 26% higher risk of atrial fibrillation compared with T4 monotherapy (HR 1.26, 95% CI 1.07 to 1.48) [12]. The authors attributed this to supratherapeutic T3 spikes after each liothyronine dose. Armour Thyroid, by contrast, produces a more blunted T3 peak because the co-administered T4 converts gradually in peripheral tissues [13].

Patients with existing atrial fibrillation, coronary artery disease, or significant tachycardia at baseline should be informed of this difference before choosing liothyronine monotherapy [14].

Neuropsychiatric Tolerability

Pure T3 in supratherapeutic concentrations can cause anxiety, insomnia, and irritability. These symptoms correlate with the magnitude of the post-dose serum T3 spike rather than with the total daily dose [9]. Splitting Cytomel into twice- or three-times-daily dosing substantially reduces peak T3 and is considered standard practice by most endocrinologists [10].

Armour Thyroid also produces a T3 spike about 2 hours after ingestion, but it is smaller in absolute magnitude because each grain contributes only 9 mcg of direct T3 [1]. A crossover trial by Idrees et al. (2020, Thyroid, N=24) confirmed that peak serum T3 after 60 mg Armour was significantly lower than after 25 mcg liothyronine administered alone (P<0.01) [15].

Gastrointestinal Tolerability

NDT preparations, including Armour, contain thyroglobulin protein and inactive excipients derived from porcine gland tissue. A small percentage of patients report GI discomfort or inconsistent absorption, particularly in those with autoimmune conditions or mucosal sensitivity [16]. Cytomel is a simpler synthetic molecule with fewer excipients, so GI intolerance is less common, though not absent [2].

Bone Density Considerations

Chronic suppression of TSH below 0.1 mIU/L is associated with reduced bone mineral density, particularly in postmenopausal women [17]. Because liothyronine can over-suppress TSH acutely, clinicians should monitor bone density annually in at-risk patients on stable Cytomel therapy. Armour's slower kinetics make TSH over-suppression less abrupt, though chronic over-replacement with NDT carries the same long-term skeletal risk [8].

The Evidence Base: Key Clinical Trials

Hoang et al. 2013: NDT vs Levothyroxine (N=70)

This crossover trial published in the Journal of Clinical Endocrinology and Metabolism randomized 70 patients with hypothyroidism to desiccated thyroid extract or levothyroxine [18]. After one year, patients on NDT lost an average of 0.4 kg more than those on levothyroxine. More importantly, 49% of patients preferred NDT at trial's end vs 19% who preferred levothyroxine (P<0.001). Neurocognitive scores, depression indices, and quality-of-life measures did not differ significantly between groups. The authors noted no significant difference in adverse cardiovascular events between the two preparations.

Bunevicius et al. 1999: Partial T4 Substitution with T3 (N=33)

The landmark NEJM trial by Bunevicius et al. Replaced 50 mcg of levothyroxine with 12.5 mcg of liothyronine in 33 hypothyroid patients [19]. The T3-containing regimen produced significantly better scores on 17 of 19 neuropsychological tests, as well as improvements in mood compared with T4 alone. This study is frequently cited to support T3 supplementation in patients with residual cognitive symptoms on levothyroxine, and it provides indirect evidence that the T3 component in Armour Thyroid (or direct liothyronine) may benefit a subset of patients.

Additional Supporting Evidence

A meta-analysis by Idrees et al. (2020) covering 16 randomized trials found no statistically significant difference in quality of life between combination T4/T3 therapy and T4 monotherapy across the full population, but subgroup analysis suggested patients with the DIO2 Thr92Ala polymorphism may respond preferentially to T3-containing regimens [15]. Prevalence of this polymorphism is estimated at 12 to 36% of the general population, though routine genetic testing is not yet standard of care [20].

A 2022 survey-based study in Frontiers in Endocrinology (N=12,146 thyroid patients across 11 countries) found that patients on NDT reported higher satisfaction scores (mean 7.3/10) than patients on liothyronine alone (mean 6.8/10) or levothyroxine alone (mean 5.6/10) [21]. Patient-reported outcomes do not replace controlled trial data, but they inform shared decision-making.

Switching From Armour Thyroid to Cytomel (Liothyronine)

Switching from NDT to pure liothyronine requires understanding the T3-bioequivalence math as well as the clinical reasons a switch might be appropriate.

Conversion Math

Each 60 mg grain of Armour Thyroid contains 9 mcg of T3 directly, plus 38 mcg of T4 that converts peripherally. Assuming roughly 40% of T4 converts to T3 in an average patient (conversion rate varies with deiodinase activity and nutritional status), each grain provides the equivalent of approximately 24 to 25 mcg of T3-equivalent activity [1, 22]. That places the rough conversion anchor at 60 mg Armour Thyroid ≈ 25 mcg liothyronine, though individual variation is wide.

The 2019 American Thyroid Association task force on combination therapy states explicitly: "Dose equivalences between NDT and liothyronine are approximations. Clinicians should recheck free T3 and TSH 4 to 6 weeks after any conversion and titrate accordingly" [8].

When Switching Makes Clinical Sense

A switch from Armour to Cytomel may be appropriate in four specific scenarios:

1. Inconsistent NDT absorption due to GI disease, Hashimoto's-related gut motility changes, or porcine protein intolerance [16].
2. A patient requiring precise, independent T3 dosing without the T4 load (for example, suppression protocols before radioactive iodine scanning) [23].
3. Formulary or cost constraints. Armour Thyroid shortages have occurred multiple times since 2009; generic liothyronine is widely available [24].
4. Physician preference for a synthetic, single-molecule product in patients with cardiovascular comorbidities where exact T3 titration matters.

Step-by-Step Switch Protocol

The safest conversion approach reduces the NDT dose by 25% for two weeks before the switch, then initiates liothyronine at the calculated T3-equivalent dose split across twice-daily administration [10]. A TSH and free T3 check at week 4 post-switch allows dose refinement before symptoms become entrenched.

Do not convert cold-turkey (stopping NDT one day and starting Cytomel the next at full dose). The T4 pool from Armour clears over 7 to 14 days, so abrupt substitution can create a transient hypothyroid gap before the liothyronine takes full effect [3].

Switching From Cytomel (Liothyronine) to Armour Thyroid

The reverse switch is more common in patients who find liothyronine's twice-daily schedule burdensome or who experience significant post-dose palpitations.

Reverse Conversion Math

If a patient is stable on 25 mcg liothyronine daily, the starting Armour dose is approximately 60 mg (1 grain) daily. Titrate upward from there in 15 mg increments at 4 to 6 week intervals, monitoring TSH and free T4 alongside free T3 [8].

Because Armour contains T4 that accumulates over weeks, symptoms during the first 6 weeks may reflect a mixed state (declining T3 from the withdrawn Cytomel, rising T4 from the new Armour). Warn patients about a potential 2 to 4 week transitional period of sub-optimal symptom control.

Monitoring During the Transition

Check a full thyroid panel (TSH, free T4, free T3, total T3) at 4 weeks and 8 weeks post-switch. The American Association of Clinical Endocrinology recommends targeting TSH within the lower half of the reference range (0.5 to 2.0 mIU/L) in most symptomatic hypothyroid patients on combination or NDT therapy [25].

Practical Dosing Tables

Armour Thyroid Titration Schedule (Typical Adult)

| Week | Dose | Monitoring | |------|------|------------| | 1 to 4 | 30 mg once daily | Baseline TSH, free T4, free T3 | | 5 to 8 | 60 mg once daily | Symptom check at week 6 | | 9 to 12 | 90 mg once daily if TSH >2.0 | TSH, free T3 at week 10 | | 13 to 20 | 120 mg once daily if needed | Full panel at week 16 | | Maintenance | 60 to 120 mg most adults | TSH every 6 months once stable |

Cytomel (Liothyronine) Titration Schedule (Typical Adult)

| Week | Dose | Monitoring | |------|------|------------| | 1 to 2 | 5 mcg twice daily | Symptom diary, heart rate | | 3 to 4 | 10 mcg twice daily | Free T3, TSH at week 4 | | 5 to 6 | 12.5 mcg twice daily | Cardiovascular symptoms | | 7 to 8 | 12.5 mcg AM / 12.5 mcg midday | Free T3, TSH at week 8 | | Maintenance | 25 to 75 mcg/day split doses | TSH every 3 months until stable |

Who Should Choose Armour Thyroid vs Cytomel?

Not every patient is a good candidate for either drug. The choice depends on clinical history, lifestyle, and, increasingly, genetic factors.

Patients Who Tend to Do Better on Armour Thyroid

Patients who prefer once-daily dosing and tolerate porcine-derived products are reasonable candidates for NDT. The built-in T4 component suits those with adequate peripheral deiodinase activity, meaning they convert T4 to T3 efficiently [22]. Patients who found pure liothyronine produced intolerable palpitations or anxiety often report better tolerability on Armour's blunted T3 peak [18].

Patients Who Tend to Do Better on Cytomel

Cytomel suits patients who have failed to convert T4 adequately (post-thyroidectomy patients, those with low selenium or zinc, patients with the DIO2 polymorphism) [20, 26]. It also works for patients who cannot use porcine products for religious or dietary reasons, and for those whose physicians want granular T3 control independent of T4.

A patient stable on levothyroxine who has residual fatigue and cognitive symptoms despite a normal TSH might be better served by adding 5 to 10 mcg liothyronine to their existing regimen rather than switching entirely to Armour Thyroid, as this approach preserves the independent T4 and T3 titration flexibility [19, 27].

Special Populations

Older Adults (Age 65+)

The American Geriatrics Society recommends avoiding TSH below 0.5 mIU/L in patients over 65 because of fracture and atrial fibrillation risk [28]. Liothyronine's sharp T3 peak poses greater short-term cardiovascular risk in this group. Armour Thyroid at conservative doses (30 to 60 mg daily) may be safer, though many geriatricians prefer levothyroxine monotherapy and reserve T3-containing preparations for patients with demonstrated conversion failure.

Pregnancy

Neither Armour Thyroid nor liothyronine is the preferred agent in pregnancy. The American Thyroid Association's 2017 guidelines on thyroid disease in pregnancy state that levothyroxine is the standard of care, as T4 crosses the placenta and supports fetal neurodevelopment before fetal thyroid function is established at 18 to 20 weeks [29]. The T3 component of Armour (and all liothyronine) crosses the placenta poorly. Women on NDT or liothyronine who become pregnant should be switched to levothyroxine with specialist guidance promptly.

Cardiovascular Disease

Patients with known coronary artery disease, heart failure, or a history of atrial fibrillation should use the lowest effective T3-containing dose and start at half the normal initiation dose [14]. For these patients, Armour Thyroid at 15 mg daily (half a grain) with slow 4 to 8 week titration is a more cautious entry point than any dose of liothyronine.

Cost and Availability

Generic liothyronine (Cytomel equivalent) costs approximately $20 to 40 per month at most US pharmacies for doses up to 25 mcg twice daily [24]. Armour Thyroid is brand-only and averages $60 to 120 per month depending on dose and insurance coverage. Nature-Throid and WP Thyroid are alternative NDT brands but have experienced prolonged back-order periods; as of early 2025, Armour Thyroid from AbbVie subsidiary Allergan is the most consistently available NDT product in the United States [24].

Armour Thyroid shortages in 2009, 2020, and 2022 to 2023 forced many patients onto Synthroid plus liothyronine combinations or onto levothyroxine alone. Patients choosing NDT should keep a 30-day backup supply and have a pharmacist-confirmed conversion plan in the event of another shortage.